Adherence, Persistence, Healthcare Resource Use, and Costs in Tofacitinib-Treated Patients with Psoriatic Arthritis: Data from Two United States Claims Databases.

Phillip J Mease Eros Papademetriou Ravi PotluriEkta AgarwalJoseph Christopher CappelleriYou-Li Ling

Published in: Advances in therapy (2024)

In this USA-based claims analysis, tofacitinib adherence was numerically lower for patients with PsA receiving monotherapy vs combination therapy. Costs numerically decreased off-treatment vs on-treatment, irrespective of therapy type, driven by lower medication costs.

Keyphrases

combination therapy
healthcare
rheumatoid arthritis
prostate cancer
health insurance
stem cells
randomized controlled trial
emergency department
big data
ulcerative colitis
machine learning
metabolic syndrome
adipose tissue
open label
deep learning
bone marrow